AbbVie Qulipta Shows Benefit In Severely Afflicted Chronic Migraine Patients

 
• By Alaric DeArment

The drug could see a competitive edge over other anti-CGRP agents with new chronic migraine data plus convenience as an oral drug and potential for combination with Botox.

Migraine word written on wood block
AbbVie announced positive Phase III data for Qulipta in chronic migraine • Source: Shutterstock

More from Clinical Trials

More from R&D